This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Franz Rosa, MD, MPH; Linda J. Miwa, PharmD
Food and Drug Administration Rockville, Md

JAMA. 1991;266(22):3127.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—"A Meta-analysis of Low-Dose Aspirin for Prevention of Pregnancy-Induced Hypertensive Disease," by Imperiale and Petrulis,¹ and "A Multivariate Analysis of Risk Factors for Preeclampsia," by Eskenazi et al,² add to the growing knowledge^3,4 of the potential to improve pregnancy outcome with daily low-dose aspirin starting in the second trimester. The meta-analysis combines studies for preventing pregnancy-induced hypertension with those for preventing recurrent fetal growth retardation. An additional recent study by Uzan et al⁵ provides more extensive data supporting prevention of fetal growth retardation with aspirin. Thus, thromboxane-induced placental insufficiency does not appear to be limited to pregnancies with hypertension.

The published data suggest that pregnancy risk groups to be considered for low-dose aspirin include (1) primiparae, especially those who are black, and (2) women with (a) previous pre-eclampsia, (b) a history of previous fetal growth retardation not explained by other causes, and (c . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?